The pharmacogenetics of codeine hypoalgesia

Area of Science:

• Pharmacology
• Genetics
• Pain Management

Background:

• Codeine is a widely used analgesic for mild to moderate pain.
• Its metabolism involves glucuronidation and minor pathways, including O-demethylation to morphine.
• The O-demethylation pathway is dependent on the polymorphic CYP2D6 enzyme.

Purpose of the Study:

• To investigate the role of CYP2D6-mediated morphine formation in codeine's analgesic effect.
• To explore potential drug interactions affecting codeine's efficacy.

Main Methods:

• Review of existing studies on codeine metabolism and analgesic effects.
• Analysis of experimental pain data in individuals with varying CYP2D6 activity (poor metabolizers vs. extensive metabolizers).
• Consideration of CYP2D6 inhibitors' impact on codeine's pain relief.

Main Results:

• Codeine's hypoalgesic effect is linked to morphine formation via CYP2D6.
• Individuals lacking CYP2D6 activity show reduced response to codeine.
• CYP2D6 inhibitors can impair codeine's pain-relieving properties.

Conclusions:

• Codeine's analgesic efficacy relies on its conversion to morphine, primarily through CYP2D6.
• Genetic variations in CYP2D6 and drug interactions with inhibitors can significantly alter pain relief.
• Understanding these mechanisms is crucial for optimizing codeine therapy and predicting treatment outcomes.